Hydroxyzine Use and Mortality in Patients Hospitalized for COVID-19 : A Multicenter Observational Study
(1) Background: Based on its antiviral activity, anti-inflammatory properties, and functional inhibition effects on the acid sphingomyelinase/ceramide system (FIASMA), we sought to examine the potential usefulness of the H1 antihistamine hydroxyzine in patients hospitalized for COVID-19. (2) Methods: In a multicenter observational study, we included 15,103 adults hospitalized for COVID-19, of which 164 (1.1%) received hydroxyzine within the first 48 h of hospitalization, administered orally at a median daily dose of 25.0 mg (SD = 29.5). We compared mortality rates between patients who received hydroxyzine at hospital admission and those who did not, using a multivariable logistic regression model adjusting for patients' characteristics, medical conditions, and use of other medications. (3) Results: This analysis showed a significant association between hydroxyzine use and reduced mortality (AOR, 0.51; 95%CI, 0.29-0.88, p = 0.016). This association was similar in multiple sensitivity analyses. (4) Conclusions: In this retrospective observational multicenter study, the use of the FIASMA hydroxyzine was associated with reduced mortality in patients hospitalized for COVID-19. Double-blind placebo-controlled randomized clinical trials of hydroxyzine for COVID-19 are needed to confirm these results, as are studies to examine the potential usefulness of this medication for outpatients and as post-exposure prophylaxis for individuals at high risk for severe COVID-19.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Journal of clinical medicine - 10(2021), 24 vom: 15. Dez. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Sánchez-Rico, Marina [VerfasserIn] |
---|
Links: |
---|
Themen: |
COVID-19 |
---|
Anmerkungen: |
Date Revised 08.11.2023 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/jcm10245891 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM334810922 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM334810922 | ||
003 | DE-627 | ||
005 | 20231225224511.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/jcm10245891 |2 doi | |
028 | 5 | 2 | |a pubmed24n1115.xml |
035 | |a (DE-627)NLM334810922 | ||
035 | |a (NLM)34945186 | ||
035 | |a (PII)5891 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Sánchez-Rico, Marina |e verfasserin |4 aut | |
245 | 1 | 0 | |a Hydroxyzine Use and Mortality in Patients Hospitalized for COVID-19 |b A Multicenter Observational Study |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 08.11.2023 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a (1) Background: Based on its antiviral activity, anti-inflammatory properties, and functional inhibition effects on the acid sphingomyelinase/ceramide system (FIASMA), we sought to examine the potential usefulness of the H1 antihistamine hydroxyzine in patients hospitalized for COVID-19. (2) Methods: In a multicenter observational study, we included 15,103 adults hospitalized for COVID-19, of which 164 (1.1%) received hydroxyzine within the first 48 h of hospitalization, administered orally at a median daily dose of 25.0 mg (SD = 29.5). We compared mortality rates between patients who received hydroxyzine at hospital admission and those who did not, using a multivariable logistic regression model adjusting for patients' characteristics, medical conditions, and use of other medications. (3) Results: This analysis showed a significant association between hydroxyzine use and reduced mortality (AOR, 0.51; 95%CI, 0.29-0.88, p = 0.016). This association was similar in multiple sensitivity analyses. (4) Conclusions: In this retrospective observational multicenter study, the use of the FIASMA hydroxyzine was associated with reduced mortality in patients hospitalized for COVID-19. Double-blind placebo-controlled randomized clinical trials of hydroxyzine for COVID-19 are needed to confirm these results, as are studies to examine the potential usefulness of this medication for outpatients and as post-exposure prophylaxis for individuals at high risk for severe COVID-19 | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a FIASMA | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a death | |
650 | 4 | |a hydroxyzine | |
650 | 4 | |a inpatients | |
650 | 4 | |a mortality | |
650 | 4 | |a treatment | |
700 | 1 | |a Limosin, Frédéric |e verfasserin |4 aut | |
700 | 1 | |a Vernet, Raphaël |e verfasserin |4 aut | |
700 | 1 | |a Beeker, Nathanaël |e verfasserin |4 aut | |
700 | 1 | |a Neuraz, Antoine |e verfasserin |4 aut | |
700 | 1 | |a Blanco, Carlos |e verfasserin |4 aut | |
700 | 1 | |a Olfson, Mark |e verfasserin |4 aut | |
700 | 1 | |a Lemogne, Cédric |e verfasserin |4 aut | |
700 | 1 | |a Meneton, Pierre |e verfasserin |4 aut | |
700 | 1 | |a Daniel, Christel |e verfasserin |4 aut | |
700 | 1 | |a Paris, Nicolas |e verfasserin |4 aut | |
700 | 1 | |a Gramfort, Alexandre |e verfasserin |4 aut | |
700 | 1 | |a Lemaitre, Guillaume |e verfasserin |4 aut | |
700 | 1 | |a De La Muela, Pedro |e verfasserin |4 aut | |
700 | 1 | |a Salamanca, Elisa |e verfasserin |4 aut | |
700 | 1 | |a Bernaux, Mélodie |e verfasserin |4 aut | |
700 | 1 | |a Bellamine, Ali |e verfasserin |4 aut | |
700 | 1 | |a Burgun, Anita |e verfasserin |4 aut | |
700 | 1 | |a Hoertel, Nicolas |e verfasserin |4 aut | |
700 | 1 | |a On Behalf Of Ap-Hp/Université de Paris/Inserm Covid-Research Collaboration/Ap-Hp Covid Cdr Initiative/Entrepôt de Données de Santé Ap-Hp Consortium |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of clinical medicine |d 2012 |g 10(2021), 24 vom: 15. Dez. |w (DE-627)NLM230666310 |x 2077-0383 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2021 |g number:24 |g day:15 |g month:12 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/jcm10245891 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 10 |j 2021 |e 24 |b 15 |c 12 |